Evidence map›Paper›PMID 34822817›Full record

ArticleNeuropharmacology2022

The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome.

Lyndsey L Anderson, Peter T Doohan, Nicole A Hawkins, Dilara Bahceci, Sumanta Garai, Ganesh A Thakur, Jennifer A Kearney, Jonathon C Arnold

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Lyndsey L AndersonLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, NSW 2050, Australia; Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia; Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
Peter T DoohanLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, NSW 2050, Australia; Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia; Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
Nicole A HawkinsDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, IL 60611, USA.
Dilara BahceciLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, NSW 2050, Australia; Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia; Brain and Mind Centre, The University of Sydney, NSW 2050, Australia.
Sumanta GaraiDepartment of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, MA 02115, USA.
Ganesh A ThakurDepartment of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, MA 02115, USA.
Jennifer A KearneyDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, IL 60611, USA.
Jonathon C ArnoldLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, NSW 2050, Australia; Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia; Brain and Mind Centre, The University of Sydney, NSW 2050, Australia. Electronic address: jonathon.arnold@sydney.edu.au.
The University of Sydney · AUNortheastern University · USNorthwestern University · US

Funding

Genetic Modifiers of Childhood EpilepsyR01NS084959 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KEARNEY, JENNIFER A · 2014 to 2024
$4.2M
NINDS NIH HHS R01 NS084959
6 · The paper itself

Abstract

Dravet syndrome is a catastrophic childhood epilepsy with multiple seizure types that are refractory to treatment. The endocannabinoid system regulates neuronal excitability so a deficit in endocannabinoid signaling could lead to hyperexcitability and seizures. Thus, we sought to determine whether a deficiency in the endocannabinoid system might contribute to seizure phenotypes in a mouse model of Dravet syndrome and whether enhancing endocannabinoid tone is anticonvulsant. Scn1a

Indexed as

AnimalsAnticonvulsantsCannabinoid Receptor AgonistsDisease Models, AnimalEndocannabinoidsEpilepsies, MyoclonicIndolesMiceMice, 129 StrainMice, TransgenicPiperazinesPyrrolidinesReceptor, Cannabinoid, CB13-(2-nitro-1-phenylethyl)-2-phenyl-1H-indoleABX-1431AnticonvulsantsCannabinoid Receptor AgonistsCNR1 protein, mouseEndocannabinoidsIndolesPiperazinesPyrrolidinesReceptor, Cannabinoid, CB1Cannabinoid receptorDravet syndromeEndocannabinoid systemEpilepsy

Identifiers

PMID34822817
PMCPMC9514665
OpenAlexW3215375859

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.